The investment will support the company’s core areas of bioelectronic medicine, including neurological health, hemostasis, ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

NanoViricides, Inc. (NYSE American: NNVC) provided an update on its Measles drug development program, highlighting the potential of its broad-spectru ...